EUVIMEDEUVIMED entdecken
Crossref

Redefining Clinically Significant Hematuria After Holmium Enucleation of the Prostate

Laena Hines, Karen M Doersch, Mark Ninomiya, Rajat Jain, Scott O Quarrier iD

Journal of Endourology · 2023

DOI: 10.1089/end.2023.0317 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Endourology, 2023. Verfasst von Laena Hines und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Rochester Medical Center, Rochester, New York, USA. Hauptthemen laut MEDLINE: Transurethral Resection of Prostate, Prostatic Hyperplasia, Laser Therapy, Lasers, Solid-State. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Holmium laser enucleation of the prostate (HoLEP) is often offered for symptomatic prostatic enlargement at high risk for bleeding. However, prior studies define clinically significant hematuria (CSH) narrowly as the need for blood transfusion or significant decrease in hemoglobin. We sought to evaluate risk factors contributing to a broader definition of CSH, which may contribute to alteration of clinical course.

Methods

We analyzed 164 patients in a prospectively maintained database who underwent HoLEP at a single institution across two surgeons from November 2020 to April 2023. HoLEP was performed using Moses 2.0 (Boston Scientific) laser and the Piranha enucleation system (Richard Wolf). We defined CSH broadly as follows: clot retention, return to operating room, perioperative management variation due to hematuria, or continued gross hematuria past 1 month postoperatively. Univariable and multivariable ANOVAs were used. Multivariable analysis of CSH risk based on the use of antiplatelet (AP) agents or anticoagulants included correction for age, enucleation time (surrogate for case difficulty), and prostate volume.

Results

17.7% (29/164) of our patients developed CSH after HoLEP. Longer enucleation time was a mild risk factor for developing CSH (multivariate odds ratio [OR] 1.01, p = 0.02). The strongest predictor of CSH was the use of anticoagulation or AP agents (OR 2.71 p < 0.02 on univariable analysis, OR 2.34 p < 0.02 on multivariable analysis), even when aspirin 81 mg was excluded.

Conclusion

With a broadened definition, 18% of patients developed CSH following HoLEP, which impacted the clinical course. Our data suggest that the current definition of significant hematuria is too narrow and does not capture many patients whose clinical course is affected by hematuria. While safe, anticoagulants and APs significantly predicted an increased CSH risk, and patients should be counseled accordingly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transurethral Resection of ProstateProstatic HyperplasiaLaser TherapyLasers, Solid-StateMaleHumansProstateHolmiumHematuriaPlatelet Aggregation InhibitorsAnticoagulantsDisease ProgressionTreatment Outcome

Stichwörter der Autor:innen

BPHHoLEPanticoagulationantiplatelethematuria

Substanzen

HolmiumPlatelet Aggregation InhibitorsAnticoagulants

Autor:innen und Institutionen

  • Department of Urology, University of Rochester Medical Center, Rochester, New York, USA.
  • University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.

ORCID-Profile: Scott O Quarrier

Zitieren

APA

Hines, L., Doersch, K. M., Ninomiya, M., Jain, R., & Quarrier, S. O. (2023). Redefining Clinically Significant Hematuria After Holmium Enucleation of the Prostate. Journal of Endourology. https://doi.org/10.1089/end.2023.0317

Vancouver

Hines L, Doersch KM, Ninomiya M, Jain R, Quarrier SO. Redefining Clinically Significant Hematuria After Holmium Enucleation of the Prostate. Journal of Endourology. 2023. doi:10.1089/end.2023.0317

BibTeX
@article{Hines2023,
  author = {Hines, Laena and Doersch, Karen M and Ninomiya, Mark and Jain, Rajat and Quarrier, Scott O},
  title = {Redefining Clinically Significant Hematuria After Holmium Enucleation of the Prostate},
  journal = {Journal of Endourology},
  year = {2023},
  doi = {10.1089/end.2023.0317}
}
Kostenlos starten →